Immunome Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Immunome Stock Summary

Immunome competes with Anebulo Pharmaceuticals, Adagene, Acrivon Therapeutics,, AnaptysBio, and Mineralys Therapeutics,. Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania. Immunome operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Immunome Key Financial Ratios

Immunome Key Balance Sheet Accounts

Immunome Key Income Statement Accounts

Immunome Key Cash Accounts

Immunome Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Immunome's current stock value. Our valuation model uses many indicators to compare Immunome value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunome competition to find correlations between indicators driving Immunome's intrinsic value. More Info.Immunome is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Immunome's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immunome by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Immunome Systematic Risk

Today, most investors in Immunome Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunome's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Immunome growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Immunome help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immunome. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immunome based on widely used predictive technical indicators. In general, we focus on analyzing Immunome Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immunome's daily price indicators and compare them against related drivers.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.